bc 007
Nucleic acidexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 1, 2016 (NCT02955420)
Timeline
Indications
Mechanism of action
GPR160 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- bc 007
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05911009 | Phase 2 | Jun 16, 2023 | Berlin Cures GmbH |
| NCT04192214 | Phase 2 | Mar 28, 2019 | Berlin Cures GmbH |
| NCT02955420 | Phase 1 | Aug 1, 2016 | Berlin Cures GmbH, Parexel |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Berlin Cures GmbH | For profit | 3 | 3 | 2 | 2016 |
| Parexel | For profit | 1 | 0 | 1 | 2016 |
2 organizations
Page 1 / 1